Myriad Genetics Inc.
320 Wakara Way
Salt Lake City,
UT 84108
United States - Map
Phone: 801-584-3600
Fax: 801-584-3640
Website: http://www.myriad.com
Myriad Genetics, Inc., a molecular diagnostic company, focuses on the development and marketing of novel predictive medicine, personalized medicine, and prognostic medicine tests primarily in the United States. The company markets BRACAnalys medicine test for the treatment of hereditary breast and ovarian cancer; COLARIS molecular test for hereditary colorectal and uterine cancer; COLARIS AP medicine test for the treatment of hereditary colorectal cancer; and MELARIS medicine test to treat hereditary melanoma. It also offers OnDose, a personalized medicine test for colon cancer; PANEXIA, a predictive medicine test for pancreatic cancer; PREZEON, a personalized and prognostic medicine test for cancer; Prolaris, a prognostic medicine test for prostate cancer; and TheraGuide 5-FU, a personalized medicine test for drug toxicity. In addition, the company provides protein analysis services to the pharmaceutical, biotechnology, and medical research industries utilizing its multiplexed immunoassay technology. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah. Key Statistics
| |
| Myriad Genetics Inc.’s Governance Risk Indicator (GRI®) as of May 1, 2012 is: Audit (Low Concern), Board (Low Concern), Compensation (High Concern), Shareholder Rights (High Concern). | | Brought to you by Institutional Shareholder Services (ISS) |
| | Pay | Exercised | Dr. Peter D. Meldrum Ph.D.,
65
Chief Exec. Officer, Pres and Director | 1.84M | 258.00K | Dr. Walter A. Gilbert Ph.D.,
78
Founding Scientist, Vice Chairman and Member of Compensation Committee | 57.00K | N/A | Mr. James S. Evans ,
49
Chief Financial Officer, Principal Accounting Officer and Treasurer | 680.00K | 10.00K | Mr. Richard M. Marsh Esq.,
54
Exec. VP, Gen. Counsel and Sec. | 642.00K | 1.19M | Dr. Jerry S. Lanchbury Ph.D.,
54
Chief Scientific Officer | 619.00K | 880.00K |
|
| | Amounts are as of Dec 31, 2011 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year. | | Currency in USD. |
|
0.60% Nasdaq